Announcements Trials
Browse Landscape

Phase

Phase 4 4Phase 3 4Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 10INDUSTRY 4NETWORK 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myasthenia Gravis 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Carboplatin 314Paclitaxel 302Cisplatin 250Docetaxel 237pembrolizumab 230Gemcitabine 213Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 120Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 92Prednisone 91Oxaliplatin 89atezolizumab 73Leucovorin 71durvalumab 69130-nm albumin-bound paclitaxel 67Injections 64Lenalidomide 63Irinotecan 60Bortezomib 55Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Tacrolimus × Clear all
NCT04095858 2023-02-08

CATHY

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3 Terminated
11 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01325571 2016-03-09

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis

Astellas Pharma Inc

Phase 3 Completed
83 enrolled

Myasthenia Gravis

NCT00309088 2014-08-25

FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients

Astellas Pharma Inc

Phase 3 Completed
80 enrolled

Myasthenia Gravis

NCT00309101 2009-06-03

An Open Study for Steroid Resistant, Non-Thymectomized MG Patients

Astellas Pharma Inc

Phase 3 Completed
11 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡